The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.

PPTA works globally to:

-Advocate for access to and affordability of therapies for patients

-Engage in constructive dialogue with regulatory agencies

-Collaborate with patient advocacy organizations

PPTA also administers standards and programs that help ensure the quality and safety

of plasma collection and manufacturing and protect both donors and patients.